Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists

J Jones; R Panaccione; ML Russell; R Hilsden

doi:10.1155/2011/837847

Canadian Journal of Gastroenterology (Jan 2011)

Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists

J Jones,
R Panaccione,
ML Russell,
R Hilsden

Affiliations

J Jones: Departments of Medicine and Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
R Panaccione: Department of Medicine, University of Calgary, Calgary, Alberta, Canada
ML Russell: Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
R Hilsden: Department of Medicine, University of Calgary, Calgary, Alberta, Canada

DOI: https://doi.org/10.1155/2011/837847
Journal volume & issue: Vol. 25, no. 10
pp. 565 – 569

Abstract

Read online

BACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006.

Published in Canadian Journal of Gastroenterology

ISSN: 0835-7900 (Print); 1916-7237 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://www.hindawi.com/journals/cjgh/

About the journal